Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albuvirtide add-on every 4 weeks in HIV-1 incomplete immune responders
ChiCTR2400089185Phase 4Recruiting
- Sponsor
- Wuhan Jinyintan Hospital
- Start
- Sep 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, open-label trial of albuvirtide in human immunodeficiency virus infection (HIV) and acquired immunodeficiency syndrome (AIDS) (2 arms), sponsored by Wuhan Jinyintan Hospital. Primary endpoint: Difference in CD4+ T lymphocyte count compared to baseline at 24 weeks. Started Sep 2024; status: recruiting.
02
Drugs
albuvirtide
03
Conditions
human immunodeficiency virus infection (HIV)acquired immunodeficiency syndrome (AIDS)
Beyond the preview
Go deeper on ChiCTR2400089185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400089185.